newsfilter
← Latest News
GlobeNewswire·

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

  • Liquidia Corporation announced two poster presentations at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, scheduled for September 5-9, 2026.
  • The first poster, presented by N. Kolaitis on September 7, details baseline lung morphology patterns in the ASCENT study [NCT06129240] regarding interstitial lung disease.
  • The second poster, presented by Prof. V. Cottin on September 8, covers the Re-Spire Phase 3 study evaluating the safety & efficacy of L606 (treprostinil liposome inhalation suspension) for pulmonary hypertension with interstitial lung disease.
  • YUTREPIA is an approved inhaled dry-powder treprostinil formulation using PRINT technology for treating pulmonary arterial hypertension & pulmonary hypertension associated with interstitial lung disease.
  • L606 is an investigational extended-release liposomal treprostinil administered twice daily via a next-generation nebulizer & is currently under evaluation in global pivotal studies.
  • Liquidia Corporation also markets generic Treprostinil Injection & utilizes its proprietary PRINT technology to develop precise drug particles for respiratory & vascular diseases.